SAG
MRNA icon

Spotlight Asset Group’s Moderna MRNA Stock Holding History

Spotlight Asset Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$206K Buy
+535
New +$197K 0.1% 111

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Spotlight Asset Group's MRNA Position: Q3 2021 in Review

Spotlight Asset Group opened a new position in Moderna (MRNA) in Q3 2021: 535 shares worth $206K. The stake represents 0.1% of the portfolio and ranks #111 among its holdings.

1,141 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

  • Spotlight Asset Group held 535 shares of Moderna worth $206K as of Q3 2021.
  • Moderna was a new Spotlight Asset Group position in Q3 2021.
  • Moderna made up 0.1% of Spotlight Asset Group's portfolio in Q3 2021, its #111 holding.
  • 1,141 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on Spotlight Asset Group's 13F filing for Q3 2021, filed 28 Oct 2021.